SRS Capital Advisors Inc. Increases Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

SRS Capital Advisors Inc. grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 8.5% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,480 shares of the medical research company’s stock after buying an additional 195 shares during the period. SRS Capital Advisors Inc.’s holdings in Thermo Fisher Scientific were worth $1,371,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Private Wealth Management Group LLC purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at $110,000. Brookstone Capital Management boosted its position in Thermo Fisher Scientific by 252.4% during the 1st quarter. Brookstone Capital Management now owns 4,387 shares of the medical research company’s stock worth $2,550,000 after purchasing an additional 3,142 shares during the period. Artisan Partners Limited Partnership purchased a new stake in Thermo Fisher Scientific during the 4th quarter worth $40,335,000. Leo Wealth LLC purchased a new stake in Thermo Fisher Scientific during the 4th quarter worth $1,117,000. Finally, Jump Financial LLC purchased a new stake in Thermo Fisher Scientific during the 4th quarter worth $1,399,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Up 0.7 %

Shares of Thermo Fisher Scientific stock traded up $4.45 during trading on Friday, reaching $611.33. The company had a trading volume of 1,868,789 shares, compared to its average volume of 938,285. The company has a market cap of $233.35 billion, a price-to-earnings ratio of 39.21, a price-to-earnings-growth ratio of 2.85 and a beta of 0.78. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $622.30. The firm’s fifty day moving average is $584.07 and its 200-day moving average is $577.99. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.37 and a current ratio of 1.72.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, topping the consensus estimate of $5.13 by $0.24. The firm had revenue of $10.54 billion for the quarter, compared to analyst estimates of $10.50 billion. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. Thermo Fisher Scientific’s quarterly revenue was down 1.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $5.15 earnings per share. On average, analysts anticipate that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be paid a dividend of $0.39 per share. The ex-dividend date of this dividend is Friday, September 13th. This represents a $1.56 annualized dividend and a yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.01%.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on TMO. Jefferies Financial Group reaffirmed a “buy” rating and set a $650.00 price target (up from $600.00) on shares of Thermo Fisher Scientific in a research report on Monday, June 3rd. Evercore ISI decreased their price target on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. Robert W. Baird upped their price target on shares of Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. Royal Bank of Canada boosted their price objective on shares of Thermo Fisher Scientific from $660.00 to $664.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. Finally, Raymond James boosted their price objective on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. Four investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $630.41.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the sale, the chief executive officer now owns 123,816 shares in the company, valued at $76,420,473.36. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total value of $6,172,100.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at approximately $76,420,473.36. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CAO Joseph R. Holmes sold 860 shares of the company’s stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $611.03, for a total transaction of $525,485.80. Following the completion of the transaction, the chief accounting officer now owns 1,814 shares of the company’s stock, valued at approximately $1,108,408.42. The disclosure for this sale can be found here. Insiders have sold a total of 23,084 shares of company stock worth $14,094,292 over the last quarter. 0.34% of the stock is owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.